<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the efficacy of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="164" ids="18723">nicotine</z:chebi> administration in <z:hpo ids='HP_0000726'>dementia</z:hpo>, electrical field distributions of event-related potentials (ERPs) and midlatency response (MLR) were recorded and were analyzed in terms of time and space </plain></SENT>
<SENT sid="1" pm="."><plain>The study was carried out on 22 <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and 17 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> (vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson disease</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="164" ids="18723">Nicotine</z:chebi> was delivered transdermally from a <z:chebi fb="164" ids="18723">nicotine</z:chebi> patch (22.5 to 52 mg/day) for 2 or 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Dementing patients showed abnormal ERPs in latency, amplitude and electrical field on the scalp </plain></SENT>
<SENT sid="4" pm="."><plain>Decreased amplitude and electrical field abnormality of P1 in MLR was also seen in some patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These abnormal ERPs and MLR of the patients improved after administration of <z:chebi fb="164" ids="18723">nicotine</z:chebi> especially in P300 latency of ERPs and P1 amplitude of MLR </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that <z:chebi fb="164" ids="18723">nicotine</z:chebi> administration might be useful as a cognitive enhancer in <z:hpo ids='HP_0002354'>memory impairment</z:hpo> </plain></SENT>
</text></document>